Medical/Pharmaceuticals

PROVISION Study Which Met Its Primary Endpoint Now Demonstrates Similar Clinical Outcomes for FFRangio and FFR

PROVISION Study, Prospective Randomized Trial Evaluating Clinical Outcomes of FFRangio Versus FFR Guidance, Demonstrates Similar MACE Rates at One Year PARIS, May 22, 2025 /PRNewswire/ -- Today at the annual EuroPCR conference taking place in Paris, France, Dr. Toru Tanigaki of Gifu Heart Center...

2025-05-22 15:57 2501

JEC Hosts 5th International Ophthalmology Summit, Launches Groundbreaking Digital Eye Health Platform

* Global eye experts reunite in Jakarta for JECIM 2025, after five-year hiatus * JEC showcases 41 years of ophthalmology leadership and innovation * Launch of Matapedia marks new chapter in eye health education JAKARTA, Indonesia, May 22, 2025 /PRNewswire/ -- JEC Eye Hospitals and Clinics

2025-05-22 14:00 2663

Fourth NDA for Kelun-Biotech's TROP2 ADC sacituzumab tirumotecan (sac-TMT) Accepted by the Center for Drug Evaluation

CHENGDU, China, May 22, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that a new indication application (the "Application") for the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotec...

2025-05-22 10:09 3325

AnnJi Pharmaceutical Company Announces Positive Phase 1/2a Results for AJ201 in Spinal and Bulbar Muscular Atrophy (SBMA) Patients

TAIPEI, May 22, 2025 /PRNewswire/ -- AnnJi Pharmaceutical Co., Ltd., a clinical-stage Taiwanese biotechnology company focused on addressing unmet medical needs in dermatology, neurology, and rare diseases, today announced positive results from its Phase 1/2a randomized, double-blind, placebo-con...

2025-05-22 09:21 3266

Lethal mutations in pregnancy loss

REYKJAVIK, Iceland, May 21, 2025 /PRNewswire/ -- In a study published in Nature today "Sequence diversity lost in early pregnancy," scientists from deCODE genetics, a subsidiary of Amgen, estimate that around one in 136 pregnancies are lost due to new mutations in the fetus. In other words, milli...

2025-05-21 23:00 4092

Kailo Medical Acquires REI AI to Transform the Future of Radiology Reporting

Strategic acquisition brings generative AI into structured workflows, reinforcing Kailo's mission to deliver long-term impact through trusted, collaborative innovation. MELBOURNE, May 21, 2025 /PRNewswire/ -- Kailo Medical, a global leader in structured reporting for medical imaging, today anno...

2025-05-21 20:38 2748

WHO Foundation and Laerdal Global Health announce US $12.5 million to launch massive Acute Care scale up aiming to save over 50,000 lives per year

Over half of deaths in low-and middle-income countries could be addressed with effective emergency care. GENEVA, May 21, 2025 /PRNewswire/ -- A newly-announced philanthropic partnership between Laerdal Global Health and the WHO Foundation will fund WHO to scale up acute care training for health...

2025-05-21 13:38 3706

Elyon Family Clinic Launches STD Testing Packages Amid Rising Sexual Health Awareness

SINGAPORE, May 21, 2025 /PRNewswire/ -- Elyon Family Clinic & Surgery, an STD clinic in Singapore , has expanded its diagnostic offerings with the launch of two new testing packages: the STI-7 Multiplex Panel and the Genital...

2025-05-21 10:00 1981

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation (IFLI) Announce The First Follicular Lymphoma (FL) Patient Treated with BAFF-R Targeting CAR-T Cells (PMB-CT01) Achieves a Complete Response

* The first heavily pretreated r/r FL patient dosed at City of Hope with PMB-CT01 achieved a CR at one-month post treatment. * A Total of 7/7 r/r B-NHL patients including MCL, DLBCL and FL treated with PMB-CT01 have achieved a sustained CR (1 to 29+ months) with strictly grade 1 CRS and ICAN...

2025-05-20 22:22 2417

Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-022 (CLDN18.2 ADC) In Combination with KEYTRUDA® (pembrolizumab)

- ATG-022 is Antengene's CLDN18.2 antibody-drug conjugate; KEYTRUDA® (pembrolizumab) is MSD's anti-PD-1 therapy. SHANGHAI and HONG KONG, May 20, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical compa...

2025-05-20 20:00 3025

Rockwell Automation Launches EtherNet/IP In-cabinet Solution to Help Manufacturers Build Smarter, More Efficient Panels

New offering can cut wiring time by up to 80%, speeding production and innovation MILWAUKEE, Wis., May 20, 2025 /PRNewswire/ -- Rockwell Automation, Inc. (NYSE: ROK), the world's largest company dedicated to industrial automation and digital transformation,...

2025-05-20 19:00 3308

Ascletis Announces First Participants Dosed in a U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the Treatment of Obesity

- The combination study is designed to evaluate the safety and preliminary efficacy of a single-dose of ultra-long-acting subcutaneously administered ASC47 in combination with four doses of semaglutide (0.5 mg, once-weekly) in participants with obesity. - Asan adipose-targeted, muscle-preserving...

2025-05-20 18:00 3345

Pulnovo Medical Welcomes EQT as a New Investor Following CE-MDR Approval, with Continued Support from Qiming Venture Partners

HONG KONG, May 20, 2025 /PRNewswire/ -- Pulnovo Medical, a globally recognized pioneer in medical devices for pulmonary hypertension (PH) and heart failure (HF), has received new investment from EQT Group, a top-tier global private equity firm, as a new investor, alongside continued support from ...

2025-05-20 16:53 4619

MediThinQ Enters China Through Strategic Partnership with Sinopharm, Making Wearable Surgical Displays a Reality in Operating Theatres

SINGAPORE, May 20, 2025 /PRNewswire/ -- MediThinQ , the South Korean company specialising in wearable extended reality (XR) surgical displays, announced a strategic partnership with Sinopharm, a state-owned Chinese healthcare giant and the largest pharmaceutical and med...

2025-05-20 12:50 4064

SPOT-MAS Lung: AI-Powered Blood Test Brings New Hope to High-Risk Non-Smokers in Asia

SINGAPORE, May 20, 2025 /PRNewswire/ -- In a bold step toward equitable cancer care,Gene Solutions introduces SPOT-MAS Lung , a next-generation blood-based test powered by artificial intelligence (AI) and multi-omics ...

2025-05-20 10:55 4795

PHASE Scientific Raises US$34 Million Series A Round to Advance Urine-Based Diagnostic Technology for Early Disease Detection

* Largest Series A financing round in Asia's diagnostic technology sector since 2019 underscores strong investor confidence in PHASE Scientific's breakthrough diagnostic technology and growth vision. * Investment to accelerate R&D and commercialization of cutting-edge early disease detection ...

2025-05-20 09:03 3757

Telix at ANZSNM Annual Scientific Meeting 2025

MELBOURNE, Australia, May 20, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces a strong presence at the 55th Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine (ANZSNM ASM 2025), to be held in M...

2025-05-20 06:00 3397

The Hong Kong Breast Cancer Foundation's 20th Anniversary Gala Dinner Successfully Held

Fundraising to Support Breast Cancer  Patients and Promote Breast Health Education HONG KONG, May 19, 2025 /PRNewswire/ -- Around 600 guests attended the 20th Anniversary Gala Dinner hosted by The Hong Kong Breast Cancer Foundation (HKBCF), raising funds to support breast cancer patients and pr...

2025-05-19 23:47 2631

Shanton to Present Topline Data from Phase 2b Study with SAP-001 in Refractory Gout Patients at EULAR 2025 Congress

SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout SINGAPORE and PRINCETON, N.J., May 19, 2025 /PRNewswire/ -- Shanton Pharma, a clinical-stage biotech company developing a novel treatment for gout, today announced that it will be pre...

2025-05-19 21:00 3161

Cell Impact delivers flow plates and test tools to a major player in Asia

KARLSKOGA, Sweden, May 19, 2025 /PRNewswire/ -- Cell Impact AB (publ) has signed an agreement to deliver test tools to a leading industrial player in Asia. The deal confirms Cell Impact's attractive offering and its unique forming technology. The agreement is a follow-up order from a customer wi...

2025-05-19 17:20 3335
1 ... 979899100101102103 ... 381